MetaVia Inc.
MTVAHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeMetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. Valued at $11.5M, MTVA is a micro-cap name in its sector. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Market Cap
$11.5M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-2.42
EPS (Fwd)
—
ROE
-175.7%
ROA
-58.8%
Cash
$12.6M
Total Debt
$177,000
Free CF
-$11.1M
52W Change
-76.5%
Annual Financials
Cash vs Debt
Where MTVA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MTVA finished 9.64% above its 150-day moving average ($1.66) and 41.10% below its 200-day moving average ($3.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MTVA overbought or oversold?
At the September 3, 2026 close, MTVA's RSI(14) was 84.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MetaVia Inc. holds $12.6M in cash against $177K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$11.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -175.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With cash comfortably exceeding debt, MTVA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MTVA.